Supplementary Table 3. Primers, Probes and PCR Conditions Used in the Study and the Sizes

Supplementary Table 3. Primers, probes and PCR conditions used in the study and the sizes of products.

T , °C/ Product, [Ref.] Marker Sequences ann Mg, mM bp. MSP analysis F: GGGTTTTGCGAGAGCGCG RASSF1-M 64/1.5 169 R: GCTAACAAACGCGAACCG F: GGTTTTGTGAGAGTGTGTTTAG RASSF1-Um 58/1.5 170 R: CACTAACAAACACAAACCAAAC F: TGGTTAGGCGGGGTATTTTC SEMA3B-M 58/3.0 133 R: TCAACAATAAAAACGAAAACG F: GTGGTTAGGTGGGGTATTTTT SEMA3B-Um 58/3.0 135 R: ATCAACAATAAAAACAAAAACA F: TTGAGAATGTGAGTGATTTGA RARB-M 56/2.0 145 R: AACCAATCCAACCAAAACAA F: TCGAGAACGCGAGCGATTCG RARB-Um 56/2.0 145 R: GACCAATCCAACCGAAACGA F: GAGGCGGGATTTTTAGGTTC GPX1-M 56/2.0 156 R: CTAACCGAACAACACACATAACG F: ATGAGGTGGGATTTTTAGGTTT GPX1-Um 56/2.0 153 R: ACCAAACAACACACATAACACA F: GATTTTAGTTCGTATTAATGAGTTGGCGGTTTC MIR-129-2-M 54/2.0 190 R: AACCCCGACTACAAAATCGCG F: TGATTTTAGTTTGTATTAATGAGTTGGTGGTTTTG MIR-129-2-Um 54/2.0 194 R: ACCAACCCCAACTACAAAATCACA F: TTTTATTTTCGTTGACGGGC MIR-9-1-M 56/2.0 120 R: CCCGCCTCCTAACTACTATCG F: TTTTTTTATTTTTGTTGATGGGT MIR-9-1-Um 56/2.0 120 R: CCCACCTCCTAACTACTATCACC Semi-quantitative RT-PCR F: GCAAGGATTACATCGCCCTGAACGAG MHCI* R: CATCATAGCGGTGACCACAGCTCCAA 60/2.5 1276 F: TGACTTTGTCACAGCCCAAGATAG B2M R: CAAATGCGGCATCTTCAAACCTC 64/2.5 81 F: ACTTCATCTGGGGCGTCGTG RASSF1(A) 57/2.5 341 # R: GGGTGGCTTCTTGCTGGAGGG F: TTCTTTCGTGAGACGGCGGTA SEMA3B R: CCCTGGAAGATGCTGCTGGA 58/2.5 275 F: ATCGATGCCAATACTGTCGA RARB(2) R: GACTCGATGGTCAGCACTG 55/2.5 239 F: AAGGTACTACTTATCGAGAATGTG GPX1 55/2.5 461 R: GTCAGGCTCGATGTCAATGGTCTG F: CTGGTGATTGTTGGTGATGG RHOA 58/2.5 183 R: GCGATCATAATCTTCCTGCC F: ATTTGCTGATGGCTTCGTTCTTGT # NKIRAS1 R: ACTTTCTCACTTTTTGCCCACTGC 54/2.5 201 F: GAACTATCCTTGCCAATGCCAATAT CHL1 R: TTCTGCCAGGACACGACTGC 57/2.5 153 qPCR, Primary sampling F: ACGGTCTGGAGAAATGGAGA # miR-129-2** R: GGCTTCCGGCTATTGAGTTATGTA 59 234 F: CAGGAGGCGGGGTTGGTTGTTATC # miR-9-1** R: GGGCCCCTCTGCGCAGTGTATGG 65 116 F: GCAGCACATATACTAAAATTGGAACGA # RNU6B R: AATATGGAACGCTTCACGAATTTGC 68 92 qPCR, Additional sampling F: ACCTCTGTGGCGACTTCATC RASSF1(A) 57/2.5 200 R: GTTCGTGTCCCGCTCCAC F: TGACTTTGTCACAGCCCAAGATAG B2M R: CAAATGCGGCATCTTCAAACCTC 64/2.5 81 miR-129-2*** TaqMan MicroRNA Assay, ID 000590 (Applied Biosystems, USA) RNU48 TaqMan MicroRNA Control Assay, ID 001006 (Applied Biosystems, USA) RNU6B TaqMan microRNA Control Assay, ID 001093 (Applied Biosystems, USA)

Note: Tann – PCR annealing temperature; F – forward primer; R – reverse primer; * – test for DNA contaminated cDNA (the product size for MHCI from cDNA is about 300 bp); ** – primary microRNA precursor was assayed; *** – mature microRNA was assayed; # – primers were chosen using PrimerSelect from a software package Lasergene (http://www.dnastar.com/t- primerselect.aspx).

References Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman-Gomez, J., Prosper, F. and Garcia-Foncillas, J., 2009. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125, 2737-43. doi: 10.1002/ijc.24638. Beckedorff, F.C., Ayupe, A.C., Crocci-Souza, R., Amaral, M.S., Nakaya, H.I., Soltys, D.T., Menck, C.F., Reis, E.M. and Verjovski-Almeida, S., 2013. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet 9, e1003705. doi: 10.1371/journal.pgen.1003705. Burbee, D.G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A.F., Lerman, M.I., Zabarovsky, E., White, M. and Minna, J.D., 2001. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93, 691-9. doi. Horiuchi, A., Imai, T., Wang, C., Ohira, S., Feng, Y., Nikaido, T. and Konishi, I., 2003. Up- regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83, 861-70. doi. Li, S., Yan, T., Yang, J.Q., Oberley, T.D. and Oberley, L.W., 2000. The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase. Cancer Res 60, 3927-39. doi. Loginov, V.I., Dmitriev, A.A., Senchenko, V.N., Pronina, I.V., Khodyrev, D.S., Kudryavtseva, A.V., Krasnov, G.S., Gerashchenko, G.V., Chashchina, L.I., Kazubskaya, T.P., Kondratieva, T.T., Lerman, M.I., Angeloni, D., Braga, E.A. and Kashuba, V.I., 2015. Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal Cancers. PLoS One 10, e0123369. doi: 10.1371/journal.pone.0123369. Lujambio, A., Calin, G.A., Villanueva, A., Ropero, S., Sanchez-Cespedes, M., Blanco, D., Montuenga, L.M., Rossi, S., Nicoloso, M.S., Faller, W.J., Gallagher, W.M., Eccles, S.A., Croce, C.M. and Esteller, M., 2008. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105, 13556-61. doi: 10.1073/pnas.0803055105. Min, S.Y., Kim, H.S., Jung, E.J., Jung, E.J., Jee, C.D. and Kim, W.H., 2012. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer. Anticancer Res 32, 3169-75. doi. Senchenko, V.N., Krasnov, G.S., Dmitriev, A.A., Kudryavtseva, A.V., Anedchenko, E.A., Braga, E.A., Pronina, I.V., Kondratieva, T.T., Ivanov, S.V., Zabarovsky, E.R. and Lerman, M.I., 2011. Differential expression of CHL1 gene during development of major human cancers. PLoS One 6, e15612. doi: 10.1371/journal.pone.0015612. Widschwendter, M., Berger, J., Hermann, M., Muller, H.M., Amberger, A., Zeschnigk, M., Widschwendter, A., Abendstein, B., Zeimet, A.G., Daxenbichler, G. and Marth, C., 2000. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 92, 826-32. doi. Yang, Q., Yoshimura, G., Nakamura, M., Nakamura, Y., Shan, L., Suzuma, T., Tamaki, T., Umemura, T., Mori, I. and Kakudo, K., 2001. Allelic loss of chromosome 3p24 correlates with tumor progression rather than with retinoic acid receptor beta2 expression in breast carcinoma. Breast Cancer Res Treat 70, 39-45. doi.